Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) EPS (Weighted Average and Diluted) (2021 - 2025)

C4 Therapeutics (CCCC) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.09 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 81.63% year-over-year to -$0.09; the TTM value through Dec 2025 reached -$1.27, up 16.45%, while the annual FY2025 figure was -$1.27, 16.45% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.09 in Q4 2025 per CCCC's latest filing, up from -$0.44 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.09 in Q4 2025 and bottomed at -$0.76 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.5, with a median of -$0.51 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 145.16% in 2022, then soared 81.63% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.31 in 2021, then plummeted by 145.16% to -$0.76 in 2022, then increased by 10.53% to -$0.68 in 2023, then rose by 27.94% to -$0.49 in 2024, then skyrocketed by 81.63% to -$0.09 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.09 in Q4 2025, -$0.44 in Q3 2025, and -$0.37 in Q2 2025.